CJC-1295 with DAC in Growth Research requires traceable specification (5mg) and RUO acknowledgment; CJC-1295 with DAC Specification and Vial Format Review outlines buyer steps on sulanpeptide.vip.
CJC-1295 with DAC is a modified GHRH analog peptide used in laboratory research on growth-hormone-axis signaling, peptide half-life extension, and receptor-pathway studies involving DAC-mediated albumin binding.
CJC-1295 with DAC incorporates a Drug Affinity Complex (maleimidopropionyl linker) extending half-life in GHRH receptor binding studies. Research compares DAC-modified GHRH(1-29) analogs against native GHRH pulses in pituitary somatotroph cell lines measuring GH secretagogue responses.
GH release ELISA from primary pituitary cultures and GHRH receptor internalization microscopy are common assay endpoints. Endocrine society abstracts and journal articles discuss prolonged GHRH analog exposure effects on pulsatile GH secretory pattern models in swine and rodent systems.
Side-by-side review of specification table, vial label, and COA prevents release errors for CJC-1295 with DAC. Principal investigators should sign off CJC-1295 with DAC SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (5mg) in procurement systems—do not round kit counts.
Catalog identifiers for CJC-1295 with DAC: CAS 446262-90-4, Formula: C165H269N47O46. MW 3647.25 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for CJC-1295 with DAC to support reproducibility.
Dose planning for CJC-1295 with DAC should state mass (5mg) or molarity derived from catalog molecular weight.
Molecular identifiers for CJC-1295 with DAC—CAS 446262-90-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing CJC-1295 with DAC should include these fields for reproducibility in Growth Research journals. Format selection for CJC-1295 with DAC affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for CJC-1295 with DAC. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for CJC-1295 with DAC should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
Specification alignment for CJC-1295 with DAC requires copying exact kit notation (5mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for CJC-1295 with DAC should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type. Specification alignment for CJC-1295 with DAC requires copying exact kit notation (5mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for CJC-1295 with DAC. QA sign-off should reference all four documents in the batch record.
CJC-1295 with DAC from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.